Pet Care And ONE SYM Transformation Will Drive Long-Term Market Outperformance

Catalysts

About Symrise

Symrise is a global supplier of flavors, fragrances, nutrition and cosmetic ingredients that develop innovative, science-based solutions for consumer goods companies.

What are the underlying business or industry changes driving this perspective?

• Acceleration of the ONE SYM Transformation, including global sourcing, asset management and lean manufacturing, is structurally lifting gross margins and EBITDA margin. This is expected to translate into sustained earnings growth and stronger operating leverage.
• Industry leading positions in Food and Beverage and Fine Fragrances, combined with a robust innovation pipeline such as health-focused probiotic solutions, position Symrise to outgrow a moderating but still expanding global consumer market and drive above-market revenue growth.
• Rising consumer demand for natural, wellness oriented and science backed products in areas like metabolic health and pet care supports a premium product mix and pricing power. This underpins long term margin expansion and higher earnings quality.
• Strategic portfolio pruning, including divestments of lower margin, higher capital intensity activities, is shifting the business mix toward higher value segments. This supports a structurally higher EBITDA margin range and improved return on capital.
• Disciplined capital allocation with a strong balance sheet, clear free cash flow targets around and above 14 percent of sales and selective, bolt-on M&A creates a foundation for compounding EPS growth and potential for increasing shareholder returns over time.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more optimistic perspective on Symrise compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
• The bullish analysts are assuming Symrise's revenue will grow by 5.7% annually over the next 3 years.
• The bullish analysts assume that profit margins will increase from 5.1% today to 12.5% in 3 years time.
• The bullish analysts expect earnings to reach €727.0 million (and earnings per share of €5.34) by about July 2029, up from €249.3 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 25.0x on those 2029 earnings, down from 48.1x today. This future PE is lower than the current PE for the GB Chemicals industry at 26.8x.
• The bullish analysts expect the number of shares outstanding to grow by 0.08% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.62%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• A prolonged normalization in the Pet Food market, including sustained pricing pressure in Pet Nutrition and shifts from global brands to regional or private label players, could structurally weaken one of Symrise's key growth pillars and weigh on group revenue growth and mix driven net margins over time.
• If the global consumer environment remains subdued, particularly in North America where organic sales are already slightly negative, Symrise may fail to achieve its targeted 5 to 7 percent midterm organic growth range, which would limit operating leverage and slow earnings growth.
• Ongoing portfolio restructuring, including divestments such as Aqua Feed and potential strategic alternatives for Terpene Ingredients, may not be offset quickly by higher margin replacement business. This could create execution risk that delays the intended uplift in EBITDA margin and constrains earnings expansion.
• The ONE SYM Transformation heavily depends on recurring cost savings from global procurement, asset management and lean manufacturing. If these efficiencies prove harder to sustain or require greater reinvestment in digitalization, R&D and commercial capabilities than anticipated, the structural improvement in gross margins and EBITDA margin could be smaller than planned, which would reduce long term earnings potential.
• Foreign exchange headwinds and exposure to volatile emerging market currencies, already reducing reported sales despite underlying organic growth, could persist or intensify. This could erode reported revenue and dampen net income growth even if operational performance remains solid.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Symrise is €110.0, which represents up to two standard deviations above the consensus price target of €94.89. This valuation is based on what can be assumed as the expectations of Symrise's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €110.0, and the most bearish reporting a price target of just €75.0.
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be €5.8 billion, earnings will come to €727.0 million, and it would be trading on a PE ratio of 25.0x, assuming you use a discount rate of 5.6%.
• Given the current share price of €87.62, the analyst price target of €110.0 is 20.3% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.